Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study.

IF 3.5 3区 医学 Q1 SURGERY
BJS Open Pub Date : 2025-03-04 DOI:10.1093/bjsopen/zraf047
Miriam Svensson, Pär-Ola Bendahl, Sara Alkner, Emma Hansson, Lisa Rydén, Looket Dihge
{"title":"Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study.","authors":"Miriam Svensson, Pär-Ola Bendahl, Sara Alkner, Emma Hansson, Lisa Rydén, Looket Dihge","doi":"10.1093/bjsopen/zraf047","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT. The aim of this study was to develop and validate models to stratify the risk of clinically significant SLN macrometastases (macro-SLNMs) before surgery.</p><p><strong>Methods: </strong>Women diagnosed with clinically node-negative (cN0) T1-2 breast cancer were identified within the Swedish National Quality Register for Breast Cancer (2014-2017). Prediction models and corresponding nomograms based on patient and tumour characteristics accessible before surgery were developed using adaptive least absolute shrinkage and selection operator logistic regression. The prediction of at least one and more than two macro-SLNMs adheres to the current guidelines on use of PMRT and reflects the exclusion criteria in ongoing trials aiming to de-escalate locoregional radiotherapy in patients with one or two macro-SLNMs. Predictive performance was evaluated using area under the receiver operating characteristic curve (AUC) and calibration plots.</p><p><strong>Results: </strong>Overall, 18 185 women were grouped into development (13 656) and validation (4529) cohorts. The well calibrated models predicting at least one and more than two macro-SLNMs had AUCs of 0.708 and 0.740, respectively, upon validation. By using the prediction model for at least one macro-SLNM, the risk could be updated from the pretest population prevalence of 13.2% to the post-test range of 1.6-74.6%.</p><p><strong>Conclusion: </strong>Models based on routine patient and tumour characteristics could be used for prediction of SLN status that would indicate the need for PMRT and assist decision-making on immediate breast reconstruction for patients with cN0 breast cancer.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJS Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjsopen/zraf047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT. The aim of this study was to develop and validate models to stratify the risk of clinically significant SLN macrometastases (macro-SLNMs) before surgery.

Methods: Women diagnosed with clinically node-negative (cN0) T1-2 breast cancer were identified within the Swedish National Quality Register for Breast Cancer (2014-2017). Prediction models and corresponding nomograms based on patient and tumour characteristics accessible before surgery were developed using adaptive least absolute shrinkage and selection operator logistic regression. The prediction of at least one and more than two macro-SLNMs adheres to the current guidelines on use of PMRT and reflects the exclusion criteria in ongoing trials aiming to de-escalate locoregional radiotherapy in patients with one or two macro-SLNMs. Predictive performance was evaluated using area under the receiver operating characteristic curve (AUC) and calibration plots.

Results: Overall, 18 185 women were grouped into development (13 656) and validation (4529) cohorts. The well calibrated models predicting at least one and more than two macro-SLNMs had AUCs of 0.708 and 0.740, respectively, upon validation. By using the prediction model for at least one macro-SLNM, the risk could be updated from the pretest population prevalence of 13.2% to the post-test range of 1.6-74.6%.

Conclusion: Models based on routine patient and tumour characteristics could be used for prediction of SLN status that would indicate the need for PMRT and assist decision-making on immediate breast reconstruction for patients with cN0 breast cancer.

乳腺癌乳房切除术后放疗前哨淋巴结状态预测模型的建立和验证:基于人群的研究
背景:乳房切除术后放疗(PMRT)会损害乳腺癌患者立即乳房重建的结果,前哨淋巴结(SLN)状态是评估是否需要PMRT的关键。本研究的目的是建立和验证手术前临床显著SLN大转移(macro-SLNMs)风险分层的模型。方法:诊断为临床淋巴结阴性(cN0) T1-2乳腺癌的女性在瑞典乳腺癌国家质量登记(2014-2017)中被确定。根据术前可获得的患者和肿瘤特征,使用自适应最小绝对收缩和选择算子逻辑回归开发了预测模型和相应的nomogram。对至少一种或两种以上宏观slnms的预测符合目前PMRT使用指南,并反映了正在进行的旨在降低一个或两个宏观slnms患者局部放疗降级的试验的排除标准。采用受试者工作特征曲线下面积(AUC)和标定图对预测性能进行评价。结果:总的来说,18185名妇女被分为发展(13656)和验证(4529)队列。经验证,校正良好的模型预测至少一个和两个以上宏观slnms的auc分别为0.708和0.740。通过使用至少一个宏观slnm的预测模型,可以将风险从检测前的13.2%更新到检测后的1.6-74.6%。结论:基于常规患者和肿瘤特征的模型可用于预测SLN状态,提示是否需要进行PMRT,并有助于cN0乳腺癌患者立即乳房重建的决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BJS Open
BJS Open SURGERY-
CiteScore
6.00
自引率
3.20%
发文量
144
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信